This trial is active, not recruiting.

Condition osteoarthritis
Treatment far infrared
Phase phase 1
Sponsor GAAD Medical Research Institute Inc.
Start date September 2006
End date February 2008
Trial size 2 participants
Trial identifier NCT00573352, GAAD-OA-CTP1


A study to evaluate the possibility of using far infrared radiation to manage pain due to osteoarthritis.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Far infrared radiation
far infrared
Far Infrared Radiation (5μm to 20μm wavelength). Duration is 30 to 40 minutes per session

Primary Outcomes

The primary end point is to determine the therapeutic effects of far infrared radiation on osteoarthritis
time frame: 2 years and 9 months

Secondary Outcomes

The therapeutic effects of far infrared radiation on all forms of arthritis
time frame: 2 years and 9 months

Eligibility Criteria

Male or female participants of any age.

Inclusion Criteria: - 1 year old and above Exclusion Criteria: - None

Additional Information

Official title Phase 1 Study to Determine the Efficacy of Using Energy Specific Far Infrared (FIR) Radiation for the Treatment of Arthritis and Other Related Diseases
Principal investigator Ken Nedd, M.D.
Description Arthritis consists of more than 100 different conditions. These conditions range from relatively mild forms such as tendonitis and bursitis to crippling forms as rheumatoid arthritis. Pain syndromes include fibromyalgia and arthritis-related disorders as lupus erythematosus that involve every part of the body. There are forms of the disease, such as gout that almost nobody connects with arthritis. Osteoarthritis is the most common form of arthritis. The objective for the study is to access the possibility of using far infrared radiation for pain management.
Trial information was received from ClinicalTrials.gov and was last updated in January 2009.
Information provided to ClinicalTrials.gov by GAAD Medical Research Institute Inc..